储存和处理
包装出售的产品
ALIQOPA小瓶必须在2°C至8°C(36°F至46°F)的温度下冷藏。
重构后的产品
立即管理重构和稀释的溶液。 否则,请在2°C至8°C(36°F至46°F)的温度下冷藏,并在24小时内使用。冷藏后,请在使用前让产品适应室温。 避免将稀释溶液暴露在直射阳光下。
仅与0.9%氯化钠注射液USP溶液混合。请勿将ALIQOPA与其他药物或其他稀释剂混合或注射[请参阅剂量和用法]。
完整说明资料附件: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ade50241-2c10-4038-b4e9-72f6bf905f03
--------------------------------------
Aliqopa is a pan-type I phosphatidylinositol-3 kinase(PI3K)inhibitor.In the United States, Aliqopa received accelerated FDA approval in September 2017 for use in adult patients with follicular lymphoma(FL)who have previously received at least 2 systemic therapies and have relapsed. Continued approval for this indication will depend on the verification and description of clinical benefits in confirmatory trials. PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
NDC 50419-385-01
Rx only
Aliqopa (copanlisib)
60mg*
*Equivalent to 69.1 mg copanlisib dihydrochloride
For intravenous infusion only.
Must be reconstituted and diluted.
Single dose vial - discard unused portion